{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:37:43Z","timestamp":1794573463076,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF TACTICAL AWARD"],"award-info":[{"award-number":["PCF TACTICAL AWARD"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01509-2","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:07:52Z","timestamp":1759309672000},"page":"613-629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-2414","authenticated-orcid":false,"given":"John P.","family":"Murad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-8959","authenticated-orcid":false,"given":"Reginaldo","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa J.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Hee Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lupita S.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-5872","authenticated-orcid":false,"given":"Jason","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candi","family":"Trac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"Adkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-0725","authenticated-orcid":false,"given":"Wen-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9083-9859","authenticated-orcid":false,"given":"Jun","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-2180","authenticated-orcid":false,"given":"John K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-2112","authenticated-orcid":false,"given":"Saul J.","family":"Priceman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1509_CR1","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff, T. B. et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 30, 1636\u20131644 (2024).","journal-title":"Nat. Med."},{"key":"1509_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/CCO.0000000000000232","volume":"27","author":"SJ Priceman","year":"2015","unstructured":"Priceman, S. J., Forman, S. J. & Brown, C. E. Smart CARs engineered for cancer immunotherapy. Curr. Opin. Oncol. 27, 466\u2013474 (2015).","journal-title":"Curr. Opin. Oncol."},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez, M. & Moon, E. K. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front. Immunol. 10, 128 (2019).","journal-title":"Front. Immunol."},{"key":"1509_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0230-9","volume":"5","author":"I Scarf\u00f2","year":"2017","unstructured":"Scarf\u00f2, I. & Maus, M. V. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J. Immunother. Cancer 5, 28 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1509_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01900-0","volume":"22","author":"P Knopf","year":"2023","unstructured":"Knopf, P. et al. Acidosis-mediated increase in IFN-\u03b3-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. Mol. Cancer 22, 207 (2023).","journal-title":"Mol. Cancer"},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034\u20131046 (2021).","journal-title":"Lancet Oncol."},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk, B. J. et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1275\u20131289 (2021).","journal-title":"Lancet Oncol."},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","volume":"14","author":"Y Jin","year":"2019","unstructured":"Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol. 14, 1378\u20131389 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3389\/fonc.2019.00767","volume":"9","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-Hodgkin lymphoma. Front. Oncol. 9, 767 (2019).","journal-title":"Front. Oncol."},{"key":"1509_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1002\/ijc.32603","volume":"146","author":"E Puca","year":"2020","unstructured":"Puca, E. et al. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors. Int. J. Cancer 146, 2518\u20132530 (2020).","journal-title":"Int. J. Cancer"},{"key":"1509_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymthe.2022.08.016","volume":"31","author":"W Shi","year":"2023","unstructured":"Shi, W. et al. A novel anti-PD-L1\/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity. Mol. Ther. 31, 66\u201377 (2023).","journal-title":"Mol. Ther."},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell, R. A., Sanjabi, S., Wrzesinski, S. H. & Licona-Lim\u00f3n, P. The polarization of immune cells in the tumour environment by TGF\u03b2. Nat. Rev. Immunol. 10, 554\u2013567 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1509_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","volume":"184","author":"CR Glassman","year":"2021","unstructured":"Glassman, C. R. et al. Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. Cell 184, 983\u2013999.e24 (2021).","journal-title":"Cell"},{"key":"1509_CR18","doi-asserted-by":"publisher","unstructured":"Hu, J. et al. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003633 (2022).","DOI":"10.1136\/jitc-2021-003633"},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"e000433","DOI":"10.1136\/jitc-2019-000433","volume":"8","author":"H Lind","year":"2020","unstructured":"Lind, H. et al. Dual targeting of TGF-\u03b2 and PD-L1 via a bifunctional anti-PD-L1\/TGF-\u03b2RII agent: status of preclinical and clinical advances. J. Immunother. Cancer 8, e000433 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1509_CR20","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541\u20132548 (1997).","journal-title":"Blood"},{"key":"1509_CR21","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41551-022-00888-0","volume":"6","author":"A Mansurov","year":"2022","unstructured":"Mansurov, A. et al. Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker. Nat. Biomed. Eng. 6, 819\u2013829 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1509_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.4049\/jimmunol.153.4.1697","volume":"153","author":"CL Nastala","year":"1994","unstructured":"Nastala, C. L. et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J. Immunol. 153, 1697\u20131706 (1994).","journal-title":"J. Immunol."},{"key":"1509_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1509_CR24","doi-asserted-by":"publisher","unstructured":"Alabanza, L. M. et al. Armored BCMA CAR T cells eliminate multiple myeloma and are resistant to the suppressive effects of TGF-\u03b2. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.832645 (2022).","DOI":"10.3389\/fimmu.2022.832645"},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064\u20135074 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1509_CR26","doi-asserted-by":"publisher","unstructured":"Shen, J. et al. An engineered concealed IL-15-R elicits tumor-specific CD8+ T cell responses through PD-1-cis delivery. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20220745 (2022).","DOI":"10.1084\/jem.20220745"},{"key":"1509_CR27","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1016\/j.ymthe.2020.07.018","volume":"28","author":"L Giuffrida","year":"2020","unstructured":"Giuffrida, L. et al. IL-15 preconditioning augments CAR T cell responses to checkpoint blockade for improved treatment of solid tumors. Mol. Ther. 28, 2379\u20132393 (2020).","journal-title":"Mol. Ther."},{"key":"1509_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1509_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40115-1","volume":"14","author":"EHJ Lee","year":"2023","unstructured":"Lee, E. H. J. et al. Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting. Nat. Commun. 14, 4737 (2023).","journal-title":"Nat. Commun."},{"key":"1509_CR30","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1016\/j.ymthe.2021.06.001","volume":"29","author":"B Liu","year":"2021","unstructured":"Liu, B. et al. Bifunctional TGF-\u03b2 trap\/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors. Mol. Ther. 29, 2949\u20132962 (2021).","journal-title":"Mol. Ther."},{"key":"1509_CR31","doi-asserted-by":"publisher","first-page":"e1532764","DOI":"10.1080\/2162402X.2018.1532764","volume":"8","author":"C Jochems","year":"2019","unstructured":"Jochems, C. et al. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. OncoImmunology 8, e1532764 (2019).","journal-title":"OncoImmunology"},{"key":"1509_CR32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.omto.2022.02.009","volume":"24","author":"CC Cubitt","year":"2022","unstructured":"Cubitt, C. C. et al. A novel fusion protein scaffold 18\/12\/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells. Mol. Ther. Oncolytics 24, 585\u2013596 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1509_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi8075","volume":"8","author":"DS Jones","year":"2022","unstructured":"Jones, D. S. et al. Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. Sci. Adv. 8, eabi8075 (2022).","journal-title":"Sci. Adv."},{"key":"1509_CR34","doi-asserted-by":"publisher","unstructured":"Knecht, J. G. et al. A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2672 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2672"},{"key":"1509_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.omtn.2023.07.020","volume":"33","author":"CA Di Trani","year":"2023","unstructured":"Di Trani, C. A. et al. Intratumoral injection of IL-12-encoding mRNA targeted to CSF1R and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure. Mol. Ther. Nucleic Acids 33, 599\u2013616 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1509_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","volume":"15","author":"M Kortylewski","year":"2009","unstructured":"Kortylewski, M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114\u2013123 (2009).","journal-title":"Cancer Cell"},{"key":"1509_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-13-31","volume":"13","author":"D Gong","year":"2012","unstructured":"Gong, D. et al. TGF\u03b2 signaling plays a critical role in promoting alternative macrophage activation. BMC Immunol. 13, 31 (2012).","journal-title":"BMC Immunol."},{"key":"1509_CR38","doi-asserted-by":"publisher","first-page":"86087","DOI":"10.18632\/oncotarget.13343","volume":"7","author":"T Qin","year":"2016","unstructured":"Qin, T. et al. A novel highly potent trivalent TGF-\u03b2 receptor trap inhibits early-stage tumorigenesis and tumor cell invasion in murine Pten-deficient prostate glands. Oncotarget 7, 86087\u201386102 (2016).","journal-title":"Oncotarget"},{"key":"1509_CR39","doi-asserted-by":"publisher","first-page":"e1349589","DOI":"10.1080\/2162402X.2017.1349589","volume":"6","author":"JM David","year":"2017","unstructured":"David, J. M. et al. A novel bifunctional anti-PD-L1\/TGF-beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 6, e1349589 (2017).","journal-title":"Oncoimmunology"},{"key":"1509_CR40","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21, 2278\u20132288 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1509_CR41","doi-asserted-by":"publisher","unstructured":"Stoiber, S. et al. Limitations in the design of chimeric antigen receptors for cancer therapy. Cells https:\/\/doi.org\/10.3390\/cells8050472 (2019).","DOI":"10.3390\/cells8050472"},{"key":"1509_CR42","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1158\/0008-5472.CAN-11-3132","volume":"72","author":"DJ Mulholland","year":"2012","unstructured":"Mulholland, D. J. et al. Pten loss and RAS\/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem\/progenitor cells. Cancer Res. 72, 1878\u20131889 (2012).","journal-title":"Cancer Res."},{"key":"1509_CR43","doi-asserted-by":"publisher","unstructured":"Bansal, D., Reimers, M. A., Knoche, E. M. & Pachynski, R. K. Immunotherapy and immunotherapy combinations in metastatic castration-resistant prostate cancer. Cancers https:\/\/doi.org\/10.3390\/cancers13020334 (2021).","DOI":"10.3390\/cancers13020334"},{"key":"1509_CR44","doi-asserted-by":"publisher","unstructured":"Lomeli, N., Bota, D., Argueta, D. & Gupta, K. NCMP-13. ID8 ovarian cancer mouse model mimics neurological sequelae of ovarian cancer in women. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noab196.584 (2021).","DOI":"10.1093\/neuonc\/noab196.584"},{"key":"1509_CR45","doi-asserted-by":"publisher","unstructured":"Murad, J. P. et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol. Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2021.02.024 (2021).","DOI":"10.1016\/j.ymthe.2021.02.024"},{"key":"1509_CR46","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI59806","volume":"122","author":"ZZ Yang","year":"2012","unstructured":"Yang, Z. Z. et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J. Clin. Invest. 122, 1271\u20131282 (2012).","journal-title":"J. Clin. Invest."},{"key":"1509_CR47","doi-asserted-by":"publisher","unstructured":"Padgett, L. E. et al. Nonclassical monocytes potentiate anti-tumoral CD8+ T cell responses in the lungs. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1101497 (2023).","DOI":"10.3389\/fimmu.2023.1101497"},{"key":"1509_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64158-2","volume":"10","author":"A Alkhani","year":"2020","unstructured":"Alkhani, A. et al. Ly6cLo non-classical monocytes promote resolution of rhesus rotavirus-mediated perinatal hepatic inflammation. Sci. Rep. 10, 7165 (2020).","journal-title":"Sci. Rep."},{"key":"1509_CR49","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.1073\/pnas.1424795112","volume":"112","author":"MT Cheah","year":"2015","unstructured":"Cheah, M. T. et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc. Natl Acad. Sci. USA 112, 4725\u20134730 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1509_CR50","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3389\/fimmu.2019.01147","volume":"10","author":"AE Mengos","year":"2019","unstructured":"Mengos, A. E., Gastineau, D. A. & Gustafson, M. P. The CD14+HLA-DRlo\/neg monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy. Front. Immunol. 10, 1147 (2019).","journal-title":"Front. Immunol."},{"key":"1509_CR51","doi-asserted-by":"publisher","unstructured":"Yamaguchi, Y. et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-004400 (2022).","DOI":"10.1136\/jitc-2021-004400"},{"key":"1509_CR52","doi-asserted-by":"publisher","first-page":"15889","DOI":"10.1073\/pnas.1905646116","volume":"116","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. A tumor-targeted immune checkpoint blocker. Proc. Natl Acad. Sci. USA 116, 15889\u201315894 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1509_CR53","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1073\/pnas.1203479109","volume":"109","author":"P Yu","year":"2012","unstructured":"Yu, P. et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced interleukin-15 efficacy in a prostate tumor model. Proc. Natl Acad. Sci. USA 109, 6187\u20136192 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1509_CR54","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton, L. V. et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl Acad. Sci. USA 113, E7788\u2013E7797 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1509_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1535-7163.MCT-20-0457","volume":"20","author":"SA Martomo","year":"2021","unstructured":"Martomo, S. A. et al. Single-dose anti\u2013PD-L1\/IL-15 fusion protein KD033 generates synergistic antitumor immunity with robust tumor-immune gene signatures and memory responses. Mol. Cancer Ther. 20, 347\u2013356 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"1509_CR56","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"1509_CR57","doi-asserted-by":"publisher","unstructured":"St\u00fcber, T. et al. Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2020-000676 (2020).","DOI":"10.1136\/jitc-2020-000676"},{"key":"1509_CR58","first-page":"1017","volume":"35","author":"RF Meredith","year":"1994","unstructured":"Meredith, R. F. et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. 35, 1017\u20131022 (1994).","journal-title":"J. Nucl. Med."},{"key":"1509_CR59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","volume":"4","author":"A Mansurov","year":"2020","unstructured":"Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. 4, 531\u2013543 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1509_CR60","doi-asserted-by":"publisher","first-page":"2198185","DOI":"10.1080\/2162402X.2023.2198185","volume":"12","author":"PG Pavicic Jr","year":"2023","unstructured":"Pavicic, P. G. Jr et al. Immunotherapy with IL12 and PD1\/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression. Oncoimmunology 12, 2198185 (2023).","journal-title":"Oncoimmunology"},{"key":"1509_CR61","doi-asserted-by":"publisher","unstructured":"Bar, N. et al. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.129353 (2020).","DOI":"10.1172\/jci.insight.129353"},{"key":"1509_CR62","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.4049\/jimmunol.2100026","volume":"208","author":"PR Dominguez-Gutierrez","year":"2022","unstructured":"Dominguez-Gutierrez, P. R. et al. Detection of PD-L1-expressing myeloid cell clusters in the hyaluronan-enriched stroma in tumor tissue and tumor-draining lymph nodes. J. Immunol. 208, 2829\u20132836 (2022).","journal-title":"J. Immunol."},{"key":"1509_CR63","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang, H. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J. Clin. Invest. 128, 580\u2013588 (2018).","journal-title":"J. Clin. Invest."},{"key":"1509_CR64","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/gutjnl-2016-312078","volume":"66","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. Myeloid cells are required for PD-1\/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66, 124\u2013136 (2017).","journal-title":"Gut"},{"key":"1509_CR65","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.omto.2023.07.001","volume":"30","author":"N Lam","year":"2023","unstructured":"Lam, N. et al. Development of a bicistronic anti-CD19\/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions. Mol. Ther. Oncolytics 30, 132\u2013149 (2023).","journal-title":"Mol. Ther. Oncolytics"},{"key":"1509_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101695","volume":"34","author":"D Xie","year":"2023","unstructured":"Xie, D. et al. Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape. Transl. Oncol. 34, 101695 (2023).","journal-title":"Transl. Oncol."},{"key":"1509_CR67","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","volume":"40","author":"L Cherkassky","year":"2022","unstructured":"Cherkassky, L., Hou, Z., Amador-Molina, A. & Adusumilli, P. S. Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell 40, 569\u2013574 (2022).","journal-title":"Cancer Cell"},{"key":"1509_CR68","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/jir.2014.0176","volume":"35","author":"D Skrombolas","year":"2015","unstructured":"Skrombolas, D., Wylie, I., Maharaj, S. & Frelinger, J. G. Characterization of an IL-12 p40\/p35 truncated fusion protein that can inhibit the action of IL-12. J. Interferon Cytokine Res. 35, 690\u2013697 (2015).","journal-title":"J. Interferon Cytokine Res."},{"key":"1509_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","volume":"615","author":"AM Tousley","year":"2023","unstructured":"Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507\u2013516 (2023).","journal-title":"Nature"},{"key":"1509_CR70","doi-asserted-by":"publisher","unstructured":"Makkouk, A. et al. Off-the-shelf V\u03b41 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003441 (2021).","DOI":"10.1136\/jitc-2021-003441"},{"key":"1509_CR71","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Advances in engineered macrophages: a new frontier in cancer immunotherapy. Cell Death Dis. 15, 238 (2024).","journal-title":"Cell Death Dis."},{"key":"1509_CR72","doi-asserted-by":"publisher","unstructured":"Karvouni, M., Vidal-Manrique, M., Lundqvist, A. & Alici, E. Engineered NK cells against cancer and their potential applications beyond. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.825979 (2022).","DOI":"10.3389\/fimmu.2022.825979"},{"key":"1509_CR73","doi-asserted-by":"publisher","first-page":"112550","DOI":"10.18632\/oncotarget.22545","volume":"8","author":"T Ogawa","year":"2017","unstructured":"Ogawa, T. et al. ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway. Oncotarget 8, 112550\u2013112564 (2017).","journal-title":"Oncotarget"},{"key":"1509_CR74","doi-asserted-by":"publisher","unstructured":"Murad, J. P. et al. Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.02268 (2018).","DOI":"10.3389\/fimmu.2018.02268"},{"key":"1509_CR75","doi-asserted-by":"publisher","unstructured":"Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz1863 (2020).","DOI":"10.1126\/scitranslmed.aaz1863"},{"key":"1509_CR76","doi-asserted-by":"publisher","unstructured":"Saul, P. et al. Development of HER2-specific chimeric antigen receptor T cells for the treatment of breast-to-brain metastasis. J. Immunother. Cancer https:\/\/doi.org\/10.1186\/2051-1426-3-S2-P121 (2015).","DOI":"10.1186\/2051-1426-3-S2-P121"},{"key":"1509_CR77","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.43","volume":"1","author":"Z Gu","year":"2022","unstructured":"Gu, Z. Complex heatmap visualization. Imeta 1, e43 (2022).","journal-title":"Imeta"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01509-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01509-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01509-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:02:46Z","timestamp":1776808966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01509-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01509-2","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.J.P. is a scientific advisor and\/or receives royalties from Imugene Ltd, Adicet Bio, Port Therapeutics, and Celularity. S.J.P., J.P.M., E.H.J.L. and S.J.F. are listed as co-inventors on a patent on the development of TAG72-targeted CAR-modified T cells for the treatment of TAG72-positive tumours, and S.J.P. and S.J.F. are listed as co-inventors on a patent on the development of PSCA-targeted CAR-modified T cells for the treatment of PSCA-positive tumours, owned by COH. S.J.P. and J.P.M. are listed as co-inventors on a patent on the development of PD-L1-targeted IL-12 fusion proteins, co-owned by USC and COH. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}